Mirae Asset Global Investments’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,388
| Closed | -$116K | – | 1691 |
|
|
2026
Q1 | $116K | Buy |
5,388
+399
| +8% | +$5.62K | ﹤0.01% | 1156 |
|
|
2025
Q4 | $46.5K | Buy |
4,989
+1,029
| +26% | +$8.6K | ﹤0.01% | 1404 |
|
|
2025
Q3 | $27.9K | Buy |
3,960
+44
| +1% | +$303 | ﹤0.01% | 1446 |
|
|
2025
Q2 | $25.5K | Buy |
3,916
+525
| +15% | +$3.61K | ﹤0.01% | 1362 |
|
|
2025
Q1 | $27.4K | Buy |
3,391
+30
| +0.9% | +$323 | ﹤0.01% | 1346 |
|
|
2024
Q4 | $43.3K | Sell |
3,361
-250
| -7% | -$3.48K | ﹤0.01% | 1288 |
|
|
2024
Q3 | $51.1K | Buy |
3,611
+1,002
| +38% | +$14.3K | ﹤0.01% | 1299 |
|
|
2024
Q2 | $36.1K | Sell |
2,609
-19,254
| -88% | -$282K | ﹤0.01% | 1301 |
|
|
2024
Q1 | $311K | Sell |
21,863
-22,259
| -50% | -$333K | ﹤0.01% | 2092 |
|
|
2023
Q4 | $644K | Buy |
44,122
+555
| +1% | +$6.73K | ﹤0.01% | 1841 |
|
|
2023
Q3 | $535K | Buy |
43,567
+8,522
| +24% | +$111K | ﹤0.01% | 1851 |
|
|
2023
Q2 | $422K | Buy |
35,045
+12,647
| +56% | +$165K | ﹤0.01% | 2019 |
|
|
2023
Q1 | $299K | Buy |
22,398
+7,106
| +46% | +$139K | ﹤0.01% | 2169 |
|
|
2022
Q4 | $329K | Buy |
15,292
+3,349
| +28% | +$68.7K | ﹤0.01% | 2100 |
|
|
2022
Q3 | $240K | Buy |
+11,943
| New | +$254K | ﹤0.01% | 2261 |
|
Other funds holding DAWN
Mirae Asset Global Investments's DAWN Position: Q2 2026 in Review
Mirae Asset Global Investments sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 5,388 shares — an estimated $116K sold.
Mirae Asset Global Investments first reported a position in DAWN in Q3 2022 and held it in 15 quarters. The position peaked at $644K in Q4 2023. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Mirae Asset Global Investments reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Mirae Asset Global Investments sold 5,388 Day One Biopharmaceuticals shares in Q2 2026, an estimated $116K.
- Mirae Asset Global Investments first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 15 quarters.
- Mirae Asset Global Investments's Day One Biopharmaceuticals position peaked at $644K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.